RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab (GMAB) to DKK 2,300 from DKK 2,400 and keeps an Outperform ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares.

Lundbeck has gained ODD from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system ...

Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Genmab A/S posted the largest decline among large stocks during the session, falling 8.3%, followed by Novo Nordisk A/S shares, which declined 8.1%. Shares of Torm PLC A declined 7.1%.

Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.